- Overview & Objectives
- Funding Support
Date
September 10, 2024Time
7:30 - 9:00pm EDTCredits
N/ADetails
Virtual (Free)
Program Overview:
This program will cover the key clinical trial findings and their implications from ESC 2024. The program is intended for cardiovascular specialists and primary care physicians.
Discussion Topics:
- HELIOS-B - Vutrisiran for transthyretin cardiomyopathy
- RESHAPE-HF2 and MATTERHORN - The role of transcatheter mitral valve repair in patients with heart failure
- OCEANIC-AF - How does the factor XI inhibitor asundexian compare vs. apixaban in AF?
- FINEARTS-HF - What is the role of finerenone in HFpEF?
- STROKESTOP II and GUARD-AF – Population screening for AF
- AZALEA-TIMI 71 - Factor XI inhibition and peri-procedural bleeding
Learning Objectives:
Following participation in this program, participants will be able to:
- Identify the clinical implications of the new data presented at ESC 2024
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice
Faculty:
- Milan Gupta, MD, FRCPC, FCCS, CPC(HC)
- Narendra Singh, MD, FRCPC, FCCS, FACC, FAHA